# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Orforglipron meets key endpoints in Phase 3 trials, showing A1C reduction, weight loss, and cardiovascular benefits for type 2 ...
In ACHIEVE-2, orforglipron lowered A1C by up to 1.7% compared to 0.8% with dapagliflozin, meeting the primary endpointIn ACHIEV...
BERLIN, Oct. 13, 2025 /PRNewswire/ -- The WHO Foundation and Lilly have announced a collaboration to financially support the ai...
Eli Lilly and Company (NYSE:LLY) today announced that new data from across its oncology portfolio and pipeline will be presente...
Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.